Biogen Inc BIIB posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship product, Tecfidera, a multiple sclerosis drug.
- Though sales of $2.8 billion came in above expectation of $2.6 billion, it decreased 25% Y/Y at actual currency and decreased 26% at constant currency.
- Multiple sclerosis revenue of $1.8 billion decreased 24% Y/Y.
- Spinraza sales increased marginally by 1% to $500 million, increased 1% Y/Y at actual currency, and decreased 3% at constant currency.
- Controversial Aduhelm revenue was $2 million.
- Biosimilars revenue of $202 million increased 18% at actual currency and +9% at constant currency.
- The Company is facing some hesitancy from hospitals and insurers over its recently approved Alzheimer's drug Aduhelm.
- Outlook: Biogen raised the total revenue outlook for FY21 to $10.65 billion to $10.85 billion from prior guidance of $10.45 billion to $10.75 billion, higher than the analyst consensus of $10.63.
- Adjusted EPS outlook remains unchanged at $17.50 to $19.00, the mid-point being lower than the analyst consensus of $18.41.
- Price Action: BIIB shares are up 0.94% at $326.00 during the premarket session on the last check Thursday.
- Photo by Arek Socha from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in